Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Rio Tinto (ADR) (RIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Rio Tinto (ADR) — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while Rio Tinto (ADR) trades at $88.44 (market cap $149.24B). The key difference: Rio Tinto (ADR) is far larger — about 152.7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Rio Tinto (ADR) pays a 5.1% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Rio Tinto (ADR) for 12 Days on average.
| MRVI | RIO | |
|---|---|---|
Market Cap | $977.37M | $149.24B |
Volume | 2,742,564 | 2,122,105 |
Sector | Health | Basic Materials |
52-Week High | $9.00 | $112.04 |
52-Week Low | $2.83 | $67.89 |
Typical Hold Time | 0 Days | 12 Days |
Enterprise Value | $1.08B | $162.59B |
Dividend Yield | — | 5.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Rio Tinto (RIO) trades at $93.06, down 1.31% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. Fundamentally, the company demonstrates strong profitability with 19.58% net income margin and 19.57% ROE, supported by recent quarterly earnings beats. Recent news highlights operational strength with 27% copper production growth at Oyu Tolgoi and maintained 2026 guidance.
The stock presents a compelling value opportunity with a 12.61 P/E ratio trading below the $103.13 consensus target. However, bearish technical momentum and legal risks from Madagascar contamination claims warrant caution. Analyst sentiment is mixed with 35% buy ratings versus 23% sell recommendations, suggesting balanced risk-reward for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Rio Tinto (ADR)
Rio Tinto is a global mining company that produces metals and minerals including iron ore, aluminium, copper, and lithium. Its operations supply materials used in construction, manufacturing, transportation, and energy systems.
Read more on RIO →
